Found: 78
Select item for more details and to access through your institution.
ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.
- Published in:
- Molecular Medicine, 2021, v. 27, n. 1, p. 1, doi. 10.1186/s10020-021-00400-5
- By:
- Publication type:
- Article
Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 11, p. 3081, doi. 10.1007/s00432-021-03901-2
- By:
- Publication type:
- Article
Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 5, p. 1137, doi. 10.1007/s00432-021-03681-9
- By:
- Publication type:
- Article
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 9, p. 2427, doi. 10.1007/s00432-020-03239-1
- By:
- Publication type:
- Article
EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.976731
- By:
- Publication type:
- Article
Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy.
- Published in:
- Chinese Journal of Lung Cancer, 2020, v. 23, n. 8, p. 701, doi. 10.3779/j.issn.1009-3419.2020.102.22
- By:
- Publication type:
- Article
Analysis of the Correlation between Molecular Structural Differences of PD-1/PD-L1 Inhibitors and Adverse Events.
- Published in:
- Chinese Journal of Lung Cancer, 2020, v. 23, n. 7, p. 603, doi. 10.3779/j.issn.1009-3419.2020.102.17
- By:
- Publication type:
- Article
Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2019, v. 22, n. 2, p. 111, doi. 10.3779/j.issn.1009-3419.2019.02.06
- By:
- Publication type:
- Article
Analysis of the First Diagnosis Symptom and Its Influencing Factors in 500 Patients with Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2018, v. 21, n. 5, p. 408, doi. 10.3779/j.issn.1009-3419.2018.05.09
- By:
- Publication type:
- Article
Treatment of Advanced Squamous Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2016, v. 19, n. 10, p. 687, doi. 10.3779/j.issn.1009-3419.2016.10.10
- By:
- Publication type:
- Article
Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma.
- Published in:
- Chinese Journal of Lung Cancer, 2016, v. 19, n. 10, p. 670, doi. 10.3779/j.issn.1009-3419.2016.10.06
- By:
- Publication type:
- Article
Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2016, v. 19, n. 10, p. 679, doi. 10.3779/j.issn.1009-3419.2016.10.08
- By:
- Publication type:
- Article
Clinicopathologic Characteristics of the Patients in the Elderly Lung Carcinoma.
- Published in:
- Chinese Journal of Lung Cancer, 2016, v. 19, n. 10, p. 675, doi. 10.3779/j.issn.1009-3419.2016.10.07
- By:
- Publication type:
- Article
Clinical Analysis of 58 Patients with Small Cell Lung Cancer Combined with Squamous Cell Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2016, v. 19, n. 10, p. 659, doi. 10.3779/j.issn.1009-3419.2016.10.04
- By:
- Publication type:
- Article
Treatment Choice for Advanced Non-small Cell Lung Cancer Patients Who Had Gradual Progression After EGFR-TKIs: 32 Cases Report.
- Published in:
- Chinese Journal of Lung Cancer, 2013, v. 16, n. 10, p. 524, doi. 10.3779/j.issn.1009-3419.2013.10.05
- By:
- Publication type:
- Article
Efficacy and Safety of Albumin-bound Paclitaxel in Treating Recurrent Advanced Non-small Cell Lung Cancer.
- Published in:
- Chinese Journal of Lung Cancer, 2013, v. 16, n. 10, p. 519, doi. 10.3779/j.issn.1009-3419.2013.10.04
- By:
- Publication type:
- Article
Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
- Published in:
- BMC Immunology, 2018, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12865-018-0249-9
- By:
- Publication type:
- Article
Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer.
- Published in:
- Cancer Research & Treatment, 2022, v. 54, n. 3, p. 753, doi. 10.4143/crt.2021.905
- By:
- Publication type:
- Article
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221082339
- By:
- Publication type:
- Article
Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
- Published in:
- Cell Communication & Signaling, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12964-023-01065-9
- By:
- Publication type:
- Article
ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
- Published in:
- Cell Communication & Signaling, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12964-022-00958-5
- By:
- Publication type:
- Article
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 3, p. 1, doi. 10.1007/s00262-024-03631-7
- By:
- Publication type:
- Article
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1681, doi. 10.1007/s00262-021-03106-z
- By:
- Publication type:
- Article
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy.
- Published in:
- Journal of Biomedical Science, 2024, v. 31, n. 1, p. 1, doi. 10.1186/s12929-024-01004-x
- By:
- Publication type:
- Article
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05388-0
- By:
- Publication type:
- Article
Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.
- Published in:
- Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05400-7
- By:
- Publication type:
- Article
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
- Published in:
- BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02470-6
- By:
- Publication type:
- Article
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10676-x
- By:
- Publication type:
- Article
Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 11, p. 12495, doi. 10.1002/cam4.5961
- By:
- Publication type:
- Article
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 13, p. 5823, doi. 10.1002/cam4.2420
- By:
- Publication type:
- Article
A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 6, p. 1116, doi. 10.1002/cam4.689
- By:
- Publication type:
- Article
EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.
- Published in:
- Frontiers in Oncology, 2021, v. 12, p. 1, doi. 10.3389/fonc.2021.713483
- By:
- Publication type:
- Article
Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR -Mutant Lung Adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.591922
- By:
- Publication type:
- Article
Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
- Published in:
- Journal of Cellular & Molecular Medicine, 2019, v. 23, n. 10, p. 6812, doi. 10.1111/jcmm.14565
- By:
- Publication type:
- Article
Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.
- Published in:
- Molecular & Clinical Oncology, 2014, v. 2, n. 1, p. 87, doi. 10.3892/mco.2013.199
- By:
- Publication type:
- Article
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 22, p. 3105, doi. 10.1111/1759-7714.14659
- By:
- Publication type:
- Article
Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 15, p. 2201, doi. 10.1111/1759-7714.14545
- By:
- Publication type:
- Article
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 4, p. 557, doi. 10.1111/1759-7714.14298
- By:
- Publication type:
- Article
ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 3, p. 338, doi. 10.1111/1759-7714.14249
- By:
- Publication type:
- Article
Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 1, p. 107, doi. 10.1111/1759-7714.14232
- By:
- Publication type:
- Article
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 21, p. 2924, doi. 10.1111/1759-7714.14156
- By:
- Publication type:
- Article
Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 20, p. 2825, doi. 10.1111/1759-7714.14113
- By:
- Publication type:
- Article
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 19, p. 2585, doi. 10.1111/1759-7714.14144
- By:
- Publication type:
- Article
Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC).
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 17, p. 2360, doi. 10.1111/1759-7714.14078
- By:
- Publication type:
- Article
Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 16, p. 2233, doi. 10.1111/1759-7714.14057
- By:
- Publication type:
- Article
Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 1, p. 40, doi. 10.1111/1759-7714.13705
- By:
- Publication type:
- Article
Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection.
- Published in:
- Thoracic Cancer, 2020, v. 11, n. 10, p. 2782, doi. 10.1111/1759-7714.13591
- By:
- Publication type:
- Article